<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003078</url>
  </required_header>
  <id_info>
    <org_study_id>ONC01P03</org_study_id>
    <nct_id>NCT03003078</nct_id>
  </id_info>
  <brief_title>A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane</brief_title>
  <acronym>PanCO</acronym>
  <official_title>An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoSil Medical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoSil Medical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy
      treatment for pancreatic cancer. This study has been designed to satisfy regulatory
      requirements.

      The clinical investigation will be conducted at approximately 15 sites in Australia, the
      United Kingdom and Europe (Belgium) involving 40 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed description

      The purpose of this research study is to investigate the safety of an active implantable
      (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer,
      in conjunction with Standard of Care (SOC) chemotherapy. OncoSil™, is an experimental
      treatment and carries the active treatment &quot;radioactive Phosphorous (32P)&quot; inside inactive
      silicon particles. Once implanted, the OncoSil™ Microparticles will stay in the tumour
      permanently. The purpose of OncoSil™, is to deliver the action of 32P directly into a
      targeted tumour to destroy cancer cells.

      40 Patients will be taking part in a single arm open label research study - which means that
      everyone in the research study will receive the investigational treatment OncoSil™, plus
      their prescribed standard chemotherapy regimen which will be either; FOLFIRINOX (FOLFIRINOX
      is the name of a combination of chemotherapy drugs used to treat advanced cancer of the
      pancreas) or gemcitabine + nab-paclitaxel (Abraxane).

      Endpoints: Primary Endpoint:

      • Safety and Tolerability

      Secondary Endpoints:

      Efficacy

        -  Local Progression Free Survival (LPFS), within the pancreas

        -  Progression Free Survival (PFS), all sites

        -  Overall Survival (OS)

        -  Body weight

        -  Impaired function

        -  Pain Scores

      The screening period will be performed within a 2 week period, followed by a treatment period
      of investigational visits which will occur weekly from Day 0 (Visit 1) until week 12, then 4
      weeks later at week 16, and then at 8-weekly intervals until study participants reach
      documented progression of disease criteria for both LPFS and PFS which marks the end of study
      participation i.e. EOS visit.

      An 8-weekly review of medical records will be used to monitor possible device or late
      radiation related adverse events, and oncology treatments/procedures administered for up to
      12 months post OncoSil™ implantation.

      Overall survival will be conducted via 8-weekly medical record reviews until study
      participant death, or until 104 weeks post the last study participant enrolled.

      Activity (Dose): The intended average absorbed radiation dose per treated tumour is 100 Gy
      (+20%).

      Risks associated with OncoSil™ and/or implantation procedure

      The following adverse events, considered to have a causal relationship with OncoSil™ or
      procedure, were recorded during previous clinical studies:

        -  Procedure-related pain

        -  Abdominal pain and discomfort

        -  Lethargy

        -  Fever

        -  Nausea and vomiting

        -  Abnormal liver function tests
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety / Tolerability of Device according to CTCAE V4.0</measure>
    <time_frame>Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner</time_frame>
    <description>as determined by the number of treatment emergent adverse events (TEAEs) evaluated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Progression free survival within the pancreas</measure>
    <time_frame>Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months.</time_frame>
    <description>Central reader review of CT changes throughout study enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - entire body</measure>
    <time_frame>Assessed from Baseline through to EOS visit - an average of 12 months.</time_frame>
    <description>Central reader review of CT changes throughout study enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>104 weeks post last patient first study visit</time_frame>
    <description>Time to participant death from enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Assessed from Baseline through to EOS visit, an average of 12 months.</time_frame>
    <description>Recorded body weight at each study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impaired function</measure>
    <time_frame>Frame: Measured at each study visit for the duration of the study, an average of 12 months</time_frame>
    <description>as measured by changes in the Karnofsky Performance Status from screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>Measured at each study visit for the duration of the study, an average of 12 months</time_frame>
    <description>As measured at each study visit using the Numerical Rating scale (NRS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tumour response</measure>
    <time_frame>Baseline measure from screening period, compared to Week 8 CT result, and then to 8 weekly CT results until local progression is determined, an average of 12 months.</time_frame>
    <description>as demonstrated by target tumour volumetric change (measured by a central reading centre)</description>
  </other_outcome>
  <other_outcome>
    <measure>tumour response</measure>
    <time_frame>As assessed at Week 12 study visit compared to Baseline assessment completed during screening period</time_frame>
    <description>as demonstrated by target tumour FDG-PET parameters (measured by a central reading centre)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unresectable Locally Advanced Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>OncoSil™ plus SOC Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OncoSil™</intervention_name>
    <description>The implantation of OncoSil™</description>
    <arm_group_label>OncoSil™ plus SOC Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven adenocarcinoma of the pancreas.

          2. Unresectable locally advanced pancreatic carcinoma. Patients with technically
             resectable tumours (T1-T3) will also be eligible, if they are deemed unresectable due
             to medical comorbidities or refusal of surgery.

          3. Pancreati c target tumour diameter of ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest
             axis), as qualified by the central reading centre.

          4. An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 - 100.

          5. Study participants ≥ 18 years of age at screening.

          6. To commence first-line standard FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapy
             (per standard of care according to the approved prescribing schedule), within 14 days
             post enrolment, with OncoSil™ implantation to occur during the fourth (4th) week of
             the first chemotherapy cycle.

          7. Provide signed Informed Consent.

          8. Willing and able to complete study procedures within the study timelines.

          9. Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).

         10. Adequate liver function: serum glutamic oxaloacetic transaminase/aspartate
             aminotransferase (SGOT/AST) and serum glutamic pyruvic transaminase/alanine
             aminotransferase (SGPT/ALT) ≤ 2 × ULN and serum bilirubin ≤ 1.5 × ULN unless Gilbert's
             syndrome has previously been confirmed for the study participant.

         11. Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute
             neutrophil count (ANC) ≥ 1,500/mm3, haemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm3

         12. Life expectancy of at least 3 months at the time of screening as judged by the
             investigator.

         13. Treated with or eligible to commence prophylactic treatment with a proton-pump
             inhibitor prior to implantation, and to continue to receive treatment for at least 6
             months post implantation.

         14. Not pregnant, and if of childbearing potential, agrees to use adequate birth control
             (hormonal or barrier method of birth control or abstinence) prior to study entry and
             during the study and agrees not to donate sperm or ova, for the duration of the study
             and 12 months post implantation of the investigational device (refer to Section 6.3.
             Permissible and Prohibited Medications/Treatments.

        Exclusion Criteria

          1. Evidence of distant metastases, based on review of baseline CT scan, as determined by
             the central reading centre.

          2. More than one primary lesion.

          3. Any prior radiotherapy or chemotherapy for pancreatic cancer.

          4. Use of other investigational agent at the time of screening, or within 30 days or five
             half-lives of Screening Visit 1, whichever is longer.

          5. Pregnant or lactating.

          6. In the opinion of the investigator, EUS directed implantation posing undue study
             participant risk e.g. previous EUS-FNA was considered technically too difficult to
             perform, or imaging demonstrates multiple collateral vessels surrounding or adjacent
             to the target tumour.

          7. History of malignancy, treated or untreated, within the past five years whether or not
             there is evidence of local recurrence or metastases, with the exception of basal cell
             carcinoma of the skin and cervical carcinoma in situ.

          8. Evidence of radiographic invasion into stomach, duodenum or peritoneum (if not certain
             confirmation must be obtained prior to enrolment).

          9. A known allergy or history of hypersensitivity to silicon, phosphorous or any of the

         10. Any other health condition that would preclude participation in the study in the
             judgment of the investigator Note: T1-T3 is determined as per The American Joint
             Committee on Cancer (AJCC) tumor/node/metastasis (TNM) classification and staging
             system for pancreatic cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Ross, MRCP MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashish Soman, MBBS</last_name>
    <phone>+61 2 9223 3344</phone>
    <email>ashish.soman@oncosil.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Kraszewski</last_name>
    <phone>+61 2 9223 3344</phone>
    <email>anna.kraszewski@oncosil.com.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corrimal Cancer Care Clinic, 20-22 Underwood St</name>
      <address>
        <city>Corrimal</city>
        <state>New South Wales</state>
        <zip>2518</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morteza Aghmesheh, MD, FRACP</last_name>
      <phone>+61 2 4285 1222</phone>
      <phone_ext>4</phone_ext>
    </contact>
    <investigator>
      <last_name>Morteza Aghmesheh, MD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Pavlakis</last_name>
      <phone>+ 61 02 9463 1172</phone>
      <email>nick.pavlakis@sydney.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Shirley Liang</last_name>
      <phone>+ 61 02 9463 1219</phone>
      <email>shirley.liang@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Nick Pavlakis, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre, St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Chantrill, MBBS, FRACP</last_name>
      <phone>+ 61 2 9355 5655</phone>
      <email>l.chantrill@garvan.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Louise Bryce</last_name>
      <phone>+61 02 9355 5705</phone>
      <email>louise.bryce@svha.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Lorraine Chantrill, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Crown Princess Mary Cancer Centre, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Nagrial, MBBS FRACP</last_name>
      <phone>+61 2 8890 6859</phone>
      <email>adnan.nagrial@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Meenal Rai</last_name>
      <phone>+61 2 8890 9517</phone>
      <email>meenal.rai@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A/Prof Nam Nguyen, MBBS FRACP</last_name>
      <phone>+61 422 113 598</phone>
      <email>quocnam.nguyen@sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Romina Safaeian</last_name>
      <phone>+61 8 7074 2189</phone>
      <email>romina.safaeian@sa.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute for Breathing and Sleep -Bowen CentreAustin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrdad Nikfarjam, MD PhD FRACS</last_name>
      <phone>+61 3 9496 5000</phone>
      <email>nikfarjam@unimelb.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Denise Sammut</last_name>
      <phone>+61 3 9496 5574</phone>
      <email>denise.sammut@austin.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Mehrdad Nikfarjam, MD PhD FRACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion T Harris, FRACP MBBS</last_name>
      <email>Marion.Harris@monashhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Kim Brewin</last_name>
      <email>kim.brewin@monashhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marion T Harris, FRACP MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Croagh, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Markman, FRACP MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew H Strickland, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shakher Ramdave, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher P Desmond, MBBS FRACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian K Jong, MBBS FRACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deepali H Nandurkar, MBBS, FRANZCR, MANZAPNM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Segelov, MBBS FRACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Hendlisz</last_name>
      <phone>+32 2 541 31 96</phone>
      <email>alain.hendlisz@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Alain Hendlisz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge Cancer Trials Centre, Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thankamma V Ajithkumar, MBBS, FRCP, FRCR</last_name>
      <phone>01223 216803</phone>
      <email>thankamma.ajithkumar@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Thankamma V Ajithkumar, MBBS,FRCP, FRCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>East Midlands</state>
        <zip>LEI 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chinenye Iwuji, BM, BSc, MRCP, MSc, PhD</last_name>
      <phone>0116 2547822</phone>
      <email>chinenye.iwuji@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Chinenye Iwuji, BM, BSc, MRCP, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust,</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J Ross, MRCP MBBS BSc</last_name>
      <email>Paul.Ross@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul J Ross, MRCP MBBS BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohana Suppiah</last_name>
      <phone>0208 38 38 360</phone>
      <email>Mohana.Suppiah@imperial.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Keyury Desai</last_name>
      <phone>0208 38 38 367</phone>
      <email>Keyury.Desai@imperial.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Harpreet Wasan, MBBS FRCP MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohini Sharma, MBBS FRACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Coyle, MBBS MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nawa Amin, MBBS MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pancreas</keyword>
  <keyword>metastases</keyword>
  <keyword>pancreatic tumour</keyword>
  <keyword>unresectable</keyword>
  <keyword>locally advanced</keyword>
  <keyword>implantable</keyword>
  <keyword>radiographic</keyword>
  <keyword>device</keyword>
  <keyword>Phosphorous-32</keyword>
  <keyword>OncoSil™</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>Abraxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

